Lutetium-177 vipivotide tetraxetan

Approved Use: indicated for the treatment of adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy.
Dose: 200 mCi every 6 weeks (maximum 6 doses)

​Brand Name: Pluvicto™
Manufacturer: Advanced Accelerator Applications (AAA) / Novartis 
Package Insert  
How Supplied: 200 mCi single-dose vial
Volume: 7.5 - 12.5 mL
Calibration:
Expiration: 5 days from date and time of calibration
NDC#: 69488-010-61
Product Website

​Clinical Guidelines: